if you agree with this then support Orion Karl Daley Presidential Candidate 2008
30 million AIDS sufferers, 3 million orphans, and its getting worse
|
Touting Prevention is not a Cure, as much as its just an Easy Opt Out when having to deal with it Promoting Abstinence in the name of Moral Values might have a quick fix appeal, but it does not address the AIDS Pandemic as it exists today in Africa, and how it is burgeoning across the globe. Condoms are a good idea of course, but it can be viewed as reliable as Abstinence is in being unreliable safe measure when dealing with the Impulsiveness Human Nature. More over, it too, does not help those who are afflicted with the AIDS disease. Lets assume both views have merit, and should not be dismissed , nor considered to be exclusive of one , or the other when addressing prevention. But lets also assume that we still have the Moral Obligation to save lives of the millions of people who are afficted by the AIDS Pandemic. Proactive Measures through Technology Technology is perpetually upgraded until it is eventually outdated. With HIV Aids drugs still in their infancy, and research needing to be furthered in a manner like any other technology, leads me to the following thoughts. Given that research should go to where it is most needed, Africa is suffering from an epidemic that some believe is worst than any plague in history. In other words, it would be naive to think this wouldn't eventually spread further across the globe. Pharmaceutical Companies, can benefit by being subsidized by other sources ( Humanitarian ) to do more research in Africa. That is on Populations which are getting wiped out by HIV. This could be construed as making people into "Ginny Pigs", but that is not the intented suggestion. Instead it is putting the Pharmcuetical Industry in the Right Place at the Right Time for the Right Reasons. 
Leveraging The Opportunity o There are working Aids drugs now which can be used as a Technology base. o The Onus to upgrade them would be on Pharmaceutical Companies, but with the constraints of not testing unknowns on a population; and providing sufficient quantities of the technology base to address the population in question. o This also proves that the technology base does work as opposed to just limited testing and then sold in the US as is the case now. For the Pharmaceutical companies to become competitive, and thereby evolve the HIV drugs, I believe a collaborative effort would be called for between them. Example, for patent deals, my question is that since any one of a participating Pharmaceutical Companies could come up with a working upgrade that could benefit another upgrade from another pharmaceutical company, then they could forge a partial ownership agreement. This enables I would hope competition, but prevent exclusivity of ownership at the same time. It is assumed there is a governing body formed to mange this. 
Meantime since Africa is pretty large, there would be lots of opportunity for space for any Pharmaceutical company for their work, and in the meantime they can save these populations, or the Human Capital of that part of the World.. In terms of Profits, and especially in the rest of the World for disseminating HIV drugs there would still be plenty to be made as there is a big market at hand. Since the research would be subsidized from more humanitarian sources, their could be agreeable caps put on the prices of such precious drugs. |